{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:40:08Z","timestamp":1791081608714,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2005,12,15]],"date-time":"2005-12-15T00:00:00Z","timestamp":1134604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2005,12,15]],"date-time":"2005-12-15T00:00:00Z","timestamp":1134604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2006,2,1]]},"DOI":"10.1038\/sj.leu.2404050","type":"journal-article","created":{"date-parts":[[2005,12,15]],"date-time":"2005-12-15T13:23:49Z","timestamp":1134653029000},"page":"212-217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome"],"prefix":"10.1038","volume":"20","author":[{"given":"P","family":"Maslak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Chanel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L H","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Soignet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P P","family":"Pandolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Guernah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Warrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Nimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,12,15]]},"reference":[{"key":"BF2404050_CR1","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nature02625","volume":"429","author":"G Egger","year":"2004","unstructured":"Egger G, Liang G, Aparicio A, Jones PA . Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429: 457\u2013463.","journal-title":"Nature"},{"key":"BF2404050_CR2","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1046\/j.1365-2141.2002.03586.x","volume":"118","author":"LK Jones","year":"2002","unstructured":"Jones LK, Saha V . Chromatin modification, leukemia and implications for therapy. Br J Heamatol 2002; 118: 714\u2013727.","journal-title":"Br J Heamatol"},{"key":"BF2404050_CR3","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/38664","volume":"389","author":"M Grunstein","year":"1997","unstructured":"Grunstein M . Histone acetylation in chromatin structure and transcription. Nature 1997; 389: 349\u2013352.","journal-title":"Nature"},{"key":"BF2404050_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0092-8674(93)90051-Q","volume":"72","author":"DY Lee","year":"1993","unstructured":"Lee DY, Hayes JJ, Pruss D, Wolffe AP . A positive role for histone acetylation in transcription factor access to DNA. Cell 1993; 72: 73\u201384.","journal-title":"Cell"},{"key":"BF2404050_CR5","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1056\/NEJMra023075","volume":"349","author":"JG Herman","year":"2003","unstructured":"Herman JG, Baylin SB . Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042\u20132054.","journal-title":"N Engl J Med"},{"key":"BF2404050_CR6","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/35895","volume":"391","author":"RJ Lin","year":"1998","unstructured":"Lin RJ, Nagy L, Inoue S, Shao W, Miller Jr WH, Evans RM . Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998; 391: 811\u2013814.","journal-title":"Nature"},{"key":"BF2404050_CR7","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1182\/blood.V92.4.1172","volume":"92","author":"W Ding","year":"1998","unstructured":"Ding W, Li Y-P, Nobile LM, Grills G, Carrera I, Paietta E et al. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RAR\u03b1 fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic and intensive chemotherapy. Blood 1998; 92: 1172\u20131183.","journal-title":"Blood"},{"key":"BF2404050_CR8","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/35901","volume":"391","author":"F Grignani","year":"1998","unstructured":"Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M et al. Fusion proteins of the retinoic acid receptor-\u03b1 recruit histone deacetylase in promyelocytic leukaemia. Nature 1998; 391: 815\u2013818.","journal-title":"Nature"},{"key":"BF2404050_CR9","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/ng0298-126","volume":"18","author":"L-Z He","year":"1998","unstructured":"He L-Z, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A . Distinct interactions of PML-RAR\u03b1 with co-repressors determine differential responses to RA in APL. Nat Genet 1998; 18: 126\u2013135.","journal-title":"Nat Genet"},{"key":"BF2404050_CR10","first-page":"569","volume":"327","author":"GJ Dover","year":"1992","unstructured":"Dover GJ, Brusilow S, Samid D . Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate. N Engl J Med 1992; 327: 569\u2013570.","journal-title":"N Engl J Med"},{"key":"BF2404050_CR11","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1056\/NEJM199609193351204","volume":"335","author":"NE Maestri","year":"1996","unstructured":"Maestri NE, Brusilow SW, Clissold DB, Bassett SS . Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med 1996; 335: 855\u2013859.","journal-title":"N Engl J Med"},{"key":"BF2404050_CR12","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1182\/blood.V80.6.1576.1576","volume":"80","author":"D Samid","year":"1992","unstructured":"Samid D, Yeh A, Prasanna P . Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate. Blood 1992; 80: 1576\u20131581.","journal-title":"Blood"},{"key":"BF2404050_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/0092-8674(75)90107-5","volume":"5","author":"A Leder","year":"1975","unstructured":"Leder A, Leder P . Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells. Cell 1975; 5: 319\u2013322.","journal-title":"Cell"},{"key":"BF2404050_CR14","first-page":"1755","volume":"3","author":"LJ Weng","year":"1997","unstructured":"Weng LJ, Samid D, Gore SD . Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. Clin Cancer Res 1997; 3: 1755\u20131762.","journal-title":"Clin Cancer Res"},{"key":"BF2404050_CR15","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood.V84.7.2122.2122","volume":"84","author":"A Chen","year":"1994","unstructured":"Chen A, Licht J, Wu Y, Hellinger N, Scher W, Waxman S . Retinoic acid is required for and potentiates differentiation of acute promyelocytic leukemia cells by non retinoid agents. Blood 1994; 84: 2122\u20132129.","journal-title":"Blood"},{"key":"BF2404050_CR16","first-page":"2292","volume":"7","author":"J Gilbert","year":"2001","unstructured":"Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y et al. A Phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 2001; 7: 2292\u20132300.","journal-title":"Clin Cancer Res"},{"key":"BF2404050_CR17","first-page":"3047","volume":"7","author":"MA Carducci","year":"2001","unstructured":"Carducci MA, Gilbert J, Bowling MK, Noe D, Eisenberger MA, Sinibaldi V et al. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 2001; 7: 3047\u20133055.","journal-title":"Clin Cancer Res"},{"key":"BF2404050_CR18","first-page":"2330","volume":"7","author":"SD Gore","year":"2001","unstructured":"Gore SD, Weng LJ, Zhai S, Figg WD, Donehower RC, Dover GJ et al. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 2001; 7: 2330\u20132339.","journal-title":"Clin Cancer Res"},{"key":"BF2404050_CR19","first-page":"963","volume":"8","author":"SD Gore","year":"2002","unstructured":"Gore SD, Weng LJ, Figg WD, Zhai S, Donehower RC, Dover G et al. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 2002; 8: 963\u2013970.","journal-title":"Clin Cancer Res"},{"key":"BF2404050_CR20","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1200\/JCO.1999.17.3.984","volume":"17","author":"SM Chang","year":"1999","unstructured":"Chang SM, Kuhn JG, Robins HI, Schold SC, Spence AM, Berger MS et al. Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol 1999; 17: 984\u2013990.","journal-title":"J Clin Oncol"},{"key":"BF2404050_CR21","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1093\/jnci\/90.21.1621","volume":"90","author":"RP Warrell Jr","year":"1998","unstructured":"Warrell Jr RP, He L-Z, Richon V, Calleja E, Pandolfi PP . Targeted transcription therapy of acute promyelocytic leukemia using an inhibitor of histone deacetylase. J Natl Cancer Inst 1998; 90: 1621\u20131625.","journal-title":"J Natl Cancer Inst"},{"key":"BF2404050_CR22","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1182\/blood.V99.4.1356","volume":"99","author":"DC Zhou","year":"2002","unstructured":"Zhou DC, Soon HK, Ding W, Schultz C, Warrell Jr RP, Gallagher RE . Frequent mutations in the ligand-binding domain of the PML-RAR\u03b1 after multiple relapses of acute promyelocytic leukemia: an analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood 2002; 99: 1356\u20131363.","journal-title":"Blood"},{"key":"BF2404050_CR23","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","volume":"20","author":"LR Silverman","year":"2002","unstructured":"Silverman LR, Demakos EP, Peterson B, Kornblith AB, Holland JC, Odchimar-Reissig R et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002; 20: 2429\u20132440.","journal-title":"J Clin Oncol"},{"key":"BF2404050_CR24","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1182\/blood-2003-03-0687","volume":"103","author":"JP Issa","year":"2004","unstructured":"Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S et al. Phase I study of low-dose prolonged exposure of the hypomethylating agent 5-aza-2\u2032-deoxycytidine (decitabine) in hematopoietic maligancies. Blood 2004; 103: 1635\u20131640.","journal-title":"Blood"},{"key":"BF2404050_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/5047","volume":"21","author":"EE Cameron","year":"1999","unstructured":"Cameron EE, Bachman KE, My\u00f6h\u00e4nen S, Herman JG, Baylin SB . Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21: 103\u2013107.","journal-title":"Nat Genet"},{"key":"BF2404050_CR26","first-page":"7089","volume":"63","author":"SA Belinsky","year":"2003","unstructured":"Belinsky SA, Klinge Dm, Stidley CA, Issa JP, Herman JG, March TH et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 2003; 63: 7089\u20137093.","journal-title":"Cancer Res"},{"key":"BF2404050_CR27","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, B\u00fcchner T, Willman CL, Estey EH et al. International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642\u20134649.","journal-title":"J Clin Oncol"},{"key":"BF2404050_CR28","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1073\/pnas.95.6.3003","volume":"95","author":"VM Richon","year":"1998","unstructured":"Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 1998; 95: 3003\u20133007.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF2404050_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1535-6108(02)00234-9","volume":"3","author":"KE Bachman","year":"2003","unstructured":"Bachman KE, Park BH, Rhee I, Rajagopalan H, Herman JG, Baylin SB et al. Histone modification and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 2003; 3: 89\u201395.","journal-title":"Cancer Cell"},{"key":"BF2404050_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S1535-6108(03)00165-X","volume":"4","author":"RW Johnstone","year":"2003","unstructured":"Johnstone RW, Licht JD . Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003; 4: 13\u201318.","journal-title":"Cancer Cell"},{"key":"BF2404050_CR31","doi-asserted-by":"publisher","first-page":"7398","DOI":"10.1073\/pnas.0306641101","volume":"101","author":"Y Kondo","year":"2004","unstructured":"Kondo Y, Shen L, Yan PS, Huang TH, Issa JP . Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylation. Proc Natl Acad Sci USA 2004; 101: 7398\u20137403.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF2404050_CR32","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1056\/NEJM199105163242002","volume":"324","author":"RP Warrell Jr","year":"1991","unstructured":"Warrell Jr RP, Frankel SR, Miller Jr WH, Scheinberg DA, Itri LM, Hittelman WN et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). N Engl J Med 1991; 324: 1385\u20131393.","journal-title":"N Engl J Med"},{"key":"BF2404050_CR33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood.V94.1.39.413a26_39_45","volume":"94","author":"JH Jansen","year":"1994","unstructured":"Jansen JH, de Ridder MC, Geertsma WM, Erpelinck CA, van Lom K, Smit EM et al. Complete remission of t(11;17) positive acute promyelocytic leukemia induced by all-trans retinoic acid and granulocyte colony-stimulating factor. Blood 1994; 94: 39\u201345.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2404050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2404050","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2404050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T01:16:08Z","timestamp":1648775768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2404050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,15]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2,1]]}},"alternative-id":["BF2404050"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2404050","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12,15]]},"assertion":[{"value":"11 October 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}